Sentry Investment Management LLC Decreases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sentry Investment Management LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 310 shares of the company’s stock after selling 51 shares during the period. Sentry Investment Management LLC’s holdings in IDEXX Laboratories were worth $128,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IDXX. First Trust Direct Indexing L.P. increased its stake in IDEXX Laboratories by 26.7% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 2,770 shares of the company’s stock valued at $1,400,000 after buying an additional 583 shares during the last quarter. Pinnacle Associates Ltd. increased its stake in IDEXX Laboratories by 9.0% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,070 shares of the company’s stock valued at $1,149,000 after buying an additional 171 shares during the last quarter. Financial Advocates Investment Management increased its stake in IDEXX Laboratories by 7.3% in the 3rd quarter. Financial Advocates Investment Management now owns 783 shares of the company’s stock valued at $396,000 after buying an additional 53 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. increased its stake in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares during the last quarter. Finally, Manitou Investment Management Ltd. increased its stake in IDEXX Laboratories by 5.5% in the 3rd quarter. Manitou Investment Management Ltd. now owns 8,833 shares of the company’s stock valued at $4,463,000 after buying an additional 462 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.4 %

IDXX opened at $457.81 on Thursday. The company has a 50 day moving average of $434.18 and a 200 day moving average of $451.92. The company has a market cap of $37.23 billion, a PE ratio of 42.91, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on IDXX shares. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.